Introduction

The cytokine, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the TNF death ligand family and is an attractive anti-neoplastic agent because it induces apoptosis in a wide range of cancerous cells, but not in normal, non-transformed cells [1]. TRAIL can interact with four distinct membrane-bound receptors (DR4/TRAIL-R1, DR5/TRAIL-R2, DcR1/TRAIL-R3 and DcR2/TRAIL-R4), all expressed ubiquitously in the body [2]. DR4 and DR5 contain a conserved cytoplasmic region called the death domain (DD) that is required for TRAIL-induced apoptosis. DcR1 and DcR2 do not have a functional DD and they act as decoy receptors
. Despite TRAIL's significant potential as anti-cancer agent, several factors may limit its application. One of these is the ability to target the ligand to the tumour stroma. [4] . Several studies demonstrated that bmMSC specifically migrate to tumours and metastases. More importantly, bmMSC could survive, proliferate and differentiate in the tumour and form a significant portion of the tumour stroma [5] . It was also shown that bmMSC engineered to secrete interferon ␤ (IFN-␤) prolonged survival of mice bearing a human breast tumour xenograft and pulmonary metastases compared to mice treated with recombinant IFN-␤ [6] . Similarly, intravenous injection of neural stem cells secreting rabbit carboxylesterase, an enzyme capable of activating the anti-cancer pro-drug CPT-11, completely eradicated a metastasing neuroblastoma and provided long-term (over 6 months) survival in 100% of the mice in the study [7] . Another [8] .
The therapeutic approaches aimed at eradication of tumours through expression of anti-cancer/pro-apoptotic proteins or prodrug activating enzymes in the tumour stroma have several advantages [3]. The major problem is how to deliver the anti-cancer gene or its product exclusively to the tumour. Adult bone marrow mesenchymal stem cells (bmMSC) can be isolated based on their ability to adhere to plastic and expand ex vivo. bmMSC are multipotent, unlikely to induce allogenic immune rejection and can be transduced with viral vectors
Mesenchymal stem cells (MSCs) can also be isolated by cardiocentesis from the human first-trimester foetal blood [9] [13, 14] . [9, 15] . 
Despite the potential of stem cells as TRAIL-delivery and targeting vehicle, neither TRAIL receptor expression nor the effect of TRAIL on these cells have been studied previously. Being non-transformed, these cells may be protected against TRAIL-induced apoptosis through high concentration of decoy receptors expressed on the cell surface or lack of expression of DR4 or DR5 receptors. We examined how bmMSC, fMSC and UCMS respond to TRAIL or selective-activation of the death-inducing TRAIL receptors in order to assess the suitability of these cells as TRAIL-delivery vehicles.
Materials and methods
Cell culture
Isolation and culture of human UCMS cells
Immunostaining of TRAIL receptors
Cell surface expression of the TRAIL receptors on cells was carried out as described before [16] .
Annexin V assay
Externalization of phosphatidylserine (PS) to the outer leaflet of the plasma membrane was detected by Annexin-V labelling followed by flow cytometry as described before [17] . 
Western blotting
Western blotting was carried out as described before [18] . 
Results and discussion
The (Fig. 2B) .
Fig. 1 Expression of DR4, DR5, DcR1 and DcR1 on the surface of foetal MSC, WJ cells (UMCS), adult bone marrow MSC, primary fibroblasts and Colo205 colon carcinoma cells. Cells in the log phase of their growth were harvested by trypsinization and labelled with DR4, DR5, DcR1 and DcR2-specific antibodies as described in Materials and Methods. The level of receptor expression was analysed by flow cytometry. The figure shows overlaid histograms of isotype control antibody (black line) and TRAIL-receptor antibody (grey line) labelled samples.
Fig. 2 Stem cells are resistant to TRAIL-induced cell death. Foetal MSC, WJ cells (UMCS), adult bone marrow MSC were treated with low (10 ng/ml) or high (500 ng/ml) dose of TRAIL (A and B), 20 nM cross-linked anti-DR4 and anti-DR5 agonistic antibodies (C) or D269H/E195R (D) for 24 hrs. Primary fibroblasts and Colo205 colon carcinoma cells were also treated and used as models of TRAIL resistant non-transformed cells and TRAIL sensitive cancer cells, respectively. (A) Effect of TRAIL on stem cell viability. The graph shows the viability expressed as average percentage of the untreated control Ϯ S.E.M. of three independent experiments (B) Induction of cell death by TRAIL. Average percentage of cell death induced Ϯ S.E.M. of three independent experiments is plotted measured by flow cytometric analysis of Annexin V stained samples. (C) Cell death induced by selective activation of DR4 and DR5 with agonistic antibodies. The graph shows average percentage cell death induced Ϯ S.E.M. of three independent experiments measured by Annexin V staining. (D) Cell death induced by selective activation of DR5 with the DR5-selective TRAIL mutant D269H/E195R. The graph shows average percentage cell death induced Ϯ S.E.M. of three independent experiments measured by Annexin V staining. (E) Expression of intracellular determinants of TRAIL sensitivity. Expression of pro-caspase-8, -9, c-FLIP and Bcl-2 proteins was detected in whole cell lysatets of bmMSC, fMSC and WJ (UMCS) cells by Western blotting. Expression of actin was also determined as a loading control.
To determine whether the DR4 and DR5 receptors are active, cells were treated with agonistic DR4-or DR5-specific antibodies or a DR5-selective TRAIL mutant (D269H/E195R [16] ) and induction of cell death was measured after 24 hrs with Annexin V staining (Fig. 2C and D) (Fig. 2E) .
To further assess the sensitivity of fMSC to selective activation of DR5, fMSC and Colo205 cells were treated with 5-20 nM anti-DR5 antibody and cell viability was measured by MTT assay (Fig. S1A) 
